## PROTOLABS

## Earnings Presentation

Q3 2020

October 29, 2020


## SAFE HARBOR

These slides and accompanying oral presentation may contain forward-looking statements. These statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results, levels of activity, performance, or achievements.



 these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise.



 or positive impact on results in any particular period. GAAP to non-GAAP reconciliations are included in this presentation.

## Q3 2020 OVERVIEW

## FINANCIAL HIGHLIGHTS | Q3

## Revenue




- Revenue of $\$ 107.5$ million, down (8.5)\% YoY
> Sequential revenue increase of 0.9\%
> 18,800 unique product developers served
- Non-GAAP EPS of \$0.67, down \$(0.09) YoY
> YoY decline primarily due to lower volume
> Non-GAAP gross margin improved to 51.7\%
> Non-GAAP EPS increased \$0.07 over Q2 2020


## REGIONAL REVENUE | Q3

| (\$M) | Q3 20 | Q3 19 | YoY <br> CHANGE $^{*}$ |
| :--- | :--- | :--- | :---: |
| Americas | $\$ 85.6$ | $\$ 92.9$ | $(8) \%$ |
| Europe | $\$ 18.9$ | $\$ 20.7$ | $(13) \%$ |
| Japan | $\$ 3.0$ | $\$ 3.8$ | $(22) \%$ |
| TOTAL | $\$ 107.5$ | $\$ 117.5$ | $(9) \%$ |

Revenue \% by Region Q3 2020

[^0]
## REVENUE BY SERVICE \| Q3



3D Printing - Revenue (\$M)


CNC Machining - Revenue


Sheet Metal - Revenue
(\$M)


## Q3 2020

DETAILED FINANCIAL INFORMATION

## FINANCIAL RESULTS | Q3

| \$M, EXCEPT <br> PER SHARE AMOUNTS | Q3 20 | Q2 20 | SEQ. <br> CHANGE | Q3 19 | YoY <br> CHANGE |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Revenue | $\$ 107.5$ | $\$ 106.6$ | $0.9 \%$ | $\$ 117.5$ | $(8.5) \%$ |
| Gross Margin | $50.8 \%$ | $49.2 \%$ | 160 bps | $50.8 \%$ | 10 bps |
| Non-GAAP <br> Operating Margin* | $20.8 \%$ | $17.6 \%$ | 320 bps | $21.6 \%$ | $(80) \mathrm{bps}$ |
| Non-GAAP <br> Earnings Per Share* | $\$ 0.67$ | $\$ 0.59$ | $12.5 \%$ | $\$ 0.76$ | $(11.8) \%$ |

## YoY GAAP to Non-GAAP P\&L \| Q3



Three Months Ended Sept. 30, 2019
GAAP Adjustments Non-GAAP*

| Three Months Ended Sept. 30, 2020 |  |  |
| ---: | ---: | ---: |
| GAAP | Adjustments | Non-GAAP* |
| $\$ 107,504$ | - | $\$ 107,504$ |
| $\underline{52,861}$ | $\underline{(989)}$ | $\underline{51,872}$ |
| $\$ 54,643$ | $\$ 989$ | $\$ 55,632$ |
| 16,705 | $(865)$ | 15,840 |
| 7,915 | $(638)$ | 7,277 |
| 12,354 | $\underline{(2,207)}$ | $\underline{10,147}$ |
| $\mathbf{3 6 , 9 7 4}$ | $(3,710)$ | $\underline{33,264}$ |
| $\$ 17,669$ | $\$ 4,699$ | $\$ 22,368$ |
| N/A | N/A | $\$ 30,039$ |

Revenue
Cost of Revenue
Gross Profit
Marketing and Sales
Research and Development
General and Administrative
Total Operating Expenses

| Income from Operations | $\$ 17,669$ | $\$ 4,699$ | $\$ 22,368$ |
| :--- | ---: | ---: | ---: |
| Adjusted EBITDA | N/A | N/A | $\$ 30,039$ |


| $\$ 117,455$ | - | $\$ 117,455$ |
| ---: | ---: | ---: |
| $\underline{57,839}$ | $\underline{(872)}$ | $\underline{56,967}$ |
| $\$ 59,616$ | $\$ 872$ | $\$ 60,488$ |
| 17,604 | $(760)$ | 16,844 |
| 8,359 | $(560)$ | 7,799 |
| $\underline{12,380}$ | $\underline{(1,879)}$ | $\underline{10,501}$ |
| $\underline{38,343}$ | $\underline{(3,199)}$ | $\underline{35,144}$ |
| $\$ 21,273$ | $\$ 4,071$ | $\$ 25,344$ |
| N/A | N/A | $\$ 32,352$ |

## \% of Revenue

50.8\% 51.7\%

| $51.7 \%$ | $50.8 \%$ | $51.5 \%$ |
| ---: | ---: | ---: |
| $14.7 \%$ | $15.0 \%$ | $14.3 \%$ |
| $6.8 \%$ | $7.1 \%$ | $6.6 \%$ |
| $\underline{9.4 \%}$ | $\underline{10.5 \%}$ | $\underline{8.9 \%}$ |
| $\mathbf{3 0 . 9 \%}$ | $\underline{32.6 \%}$ | $\underline{29.9 \%}$ |
| $20.8 \%$ | $18.1 \%$ | $21.6 \%$ |
| $27.9 \%$ | $\mathrm{~N} / \mathrm{A}$ | $27.5 \%$ |

*Non-GAAP: adjusted for stock-based compensation, intangible amortization, and
unrealized gain/loss on foreign currency. See reconciliation in Appendix.

## QoQ GAAP to Non-GAAP P\&L | Q3



Revenue
Cost of Revenue
Gross Profit
Marketing and Sales
Research and Development
General and Administrative
Total Operating Expenses

| Income from Operations | $\$ 17,669$ | $\$ 4,699$ | $\$ 22,368$ |
| :--- | ---: | ---: | ---: |

Three Months Ended June 30, 2020
GAAP Adjustments Non-GAAP*
GAAP
Adjustments
Non-GAAP*

| \% of Revenue |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
| Gross Profit | $50.8 \%$ | $51.7 \%$ | $49.2 \%$ | $50.1 \%$ |
| $\quad$ Marketing and Sales | $15.5 \%$ | $14.7 \%$ | $15.9 \%$ | $15.2 \%$ |
| Research and Development | $7.4 \%$ | $6.8 \%$ | $8.1 \%$ | $7.5 \%$ |
| $\quad$ General and Administrative | $\underline{11.5 \%}$ | $\underline{9.4 \%}$ | $\underline{11.7 \%}$ | $\underline{9.8 \%}$ |
| Total Operating Expenses | $\underline{34.4 \%}$ | $\underline{30.9 \%}$ | $\underline{32.5 \%}$ |  |
| Income from Operations | $16.4 \%$ | $20.8 \%$ | $13.5 \%$ | $17.6 \%$ |
| Adjusted EBITDA | $\mathrm{N} / \mathrm{A}$ | $27.9 \%$ | $\mathrm{~N} / \mathrm{A}$ | $\mathbf{2 4 . 5 \%}$ |

*Non-GAAP: adjusted for stock-based compensation, intangible amortization, and
unrealized gain/loss on foreign currency. See reconciliation in Appendix.

## CASH FLOW and BALANCE SHEET | Q3

| \$M | Q3 20 | Q2 20 | Q3 19 |
| :--- | :---: | :---: | :---: |
| Operating Cash Flow | $\$ 29.0$ | $\$ 31.0$ | $\$ 28.9$ |
| Capital Expenditures | $\$ 7.2$ | $\$ 19.9$ | $\$ 12.0$ |
| Share Repurchases | $\$ 0.0$ | $\$ 2.7$ | $\$ 12.1$ |
| Cash and Investments* | $\$ 200.6$ | $\$ 175.3$ | $\$ 155.0$ |
| Debt* | $\$ 0$ | $\$ 0$ | $\$ 0$ |

## PROTOLABS 2.0

## PROTOLABS 2.0 ｜OVERVIEW

## Background

Legacy systems evolved slowly and incrementallyBased on architecture from early 2000s
园 Inefficient to add new functionality

Protolabs 2.0 is a different approach
会 Will allow our systems to
scale and support
evolving customer needs

## Approach

Two components：Customer－facing eCommerce platformBack－end systems

Moving to modern software architecture and development
会 Allows enhancements with more frequent releases without disrupting other business process

## Future

Better support our customers and strategy

Enhanced functionality from external vendors

Easier path from R\＆D to the eCommerce platform

## PROTOLABS 2.0 | OCTOBER UPDATE



- Planned Launch
> Europe: November 2020
> Americas: Q1 2021


## - Customer Benefits

$>$ More intuitive interface and easier to understand part configurations
> Improved workflow and collaboration parts organized into projects
> Customer quotes are easier to understand - allowing non-technical colleagues to better understand

## FINANCIAL OUTLOOK

## Q4 2020 | OUTLOOK

## Q4 2020 Revenue

## Revenue

## \% Growth YoY

\$96M - \$106M
(14)\% - (5) $\%$

## Q4 2020 Revenue Details

- Seasonality: Q4 traditionally lower than Q3
- Anticipate Q4 COVID-19 related revenue will be lower than Q3 (\$3 million)
- Do not expect foreign currency to have a significant impact on Q4 revenue


## Additional Q4 2020 Outlook Commentary

- Non-GAAP gross margin of $\sim 51 \%+/-50$ bps
- Non-GAAP operating expenses of $\$ 36$ million to $\$ 37$ million
- Includes ~\$3 million related to Protolabs 2.0
- Non-GAAP add-backs for the quarter will include stock compensation costs of approximately $\$ 4.0$ million and amortization of approximately \$750,000
- Non-GAAP tax rate between 19\% and 20\%


## THANK YOU

## APPENDIX

## GAAP to NON-GAAP RECONCILIATION

| (\$ in thousands) | Three Months Ended September 30, 2020 |  |  |  | Ended <br> Sept 30, 2019 |  | $\begin{gathered} \% \\ \text { Change }^{2} \\ \hline \end{gathered}$ | \% Change Constant Currencies ${ }^{3}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | GAAP |  | ents ${ }^{1}$ | Non-GAAP |  | AP |  |  |
| Revenues |  |  |  |  |  |  |  |  |
| United States | \$ 85,608 | \$ | - | \$ 85,608 | \$ | 92,916 | (7.9) | (7.9) |
| Europe | 18,897 |  | (828) | 18,069 |  | 20,721 | (8.8) | (12.8) |
| Japan | 2,999 |  | (36) | 2,963 |  | 3,818 | (21.5) | (22.4) |
| Total Revenue | \$107,504 | \$ | (864) | \$ 106,640 | \$ | 117,455 | (8.5) | (9.2) |

${ }^{1}$ Revenue for the three and nine-month periods ended September 30, 2020 has been recalculated using 2019 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.
${ }^{2}$ This column presents the percentage change from GAAP revenue for the three and nine-month periods ended September 30, 2019 to GAAP revenue for the three and nine-month periods ended September 30, 2020.
${ }^{3}$ This column presents the percentage change from GAAP revenue for the three and nine-month periods ended September 30, 2019 to non-GAAP revenue for the three and nine-month periods ended September 30, 2020 (as recalculated using the foreign currency exchange rates in effect during the three- and nine-month periods ended September 30, 2019) in order to provide a constant-currency comparison.

## GAAP to NON-GAAP RECONCILIATION | EBITDA

(\$ in thousands)

GAAP net income
Amortization expense
Depreciation expense
Interest income, net
Tax expense
EBITDA
Add back:
Stock-based compensation expense
Unrealized (gain) loss on foreign currency
Total adjustments
Adjusted EBITDA
Adjusted EBITDA \% of Revenue

Three Months Ended
September 30,
\$ $\quad \frac{\mathbf{2 0 2 0}}{14,697} \quad \$ \quad \frac{\mathbf{2 0 1 9}}{16,792}$
$754 \quad 859$
7,282 6,820

| $(255)$ | $(489)$ |  |
| ---: | ---: | ---: |
| 3,700 |  | 4,709 |
|  | 28,178 | 28,691 |


| 3,945 |  | 3,212 |  |
| :---: | :---: | :---: | :---: |
|  | (84) |  | 449 |
|  | 3,861 |  | 3,661 |
| \$ | 30,039 | \$ | 32,352 |
|  | 27.9\% |  | 27.5\% |

## GAAP to NON-GAAP RECONCILIATION | EPS

(\$ in thousands, except share and per share amounts)
Non-GAAP net income, adjusted for stock-based compensation expense
Non-GAAP net income, adjusted for stock-based compensation expense,
amortization expense and unrealized (gain) loss on foreign currency
GAAP net income
Add back
Stock-based compensation expense
Amortization expense
Unrealized (gain) loss on foreign currency
Total adjustments ${ }^{1}$
Income tax benefits on adjustments ${ }^{2}$
Non-GAAP net income

| $\substack{\text { Three Months Ended } \\ \text { September 30, }}$ |  |
| :---: | :---: |
| $\underline{2020}$ | $\underline{2019}$ |

Non-GAAP net income per share:
Basic
Diluted
Shares used to compute non-GAAP net income per share:
Basic
Diluted

${ }^{\text {Stock-based compensation expense, amortization expense and unrealized (gain) loss on foreign currency w ere included in the follow ing GAAP consolidated statement of }}$ operations categories:

| Cost of revenue | \$ | 989 | \$ | 872 |
| :---: | :---: | :---: | :---: | :---: |
| Marketing and sales |  | 865 |  | 760 |
| Research and development |  | 638 |  | 560 |
| General and administrative |  | 2,207 |  | 1,879 |
| Total operating expenses |  | 3,710 |  | 3,199 |
| Other income, net |  | (84) |  | 449 |
| Total adjustments | \$ | 4,615 | \$ | 4,520 |

${ }^{2}$ For the three and nine-month periods ended September 30, 2020 and 2019, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. Our non-GAAP tax rates differ fromour GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the quarter.


[^0]:    *YoY change reflected in constant currency
    See reconciliation in Appendix.

